<DOC>
	<DOC>NCT02712359</DOC>
	<brief_summary>The purpose of this study is to evaluate the persistence of hepatitis A antibodies, approximately 8 years and 10 years post vaccination with the complete series of Havrix (2 doses) and the partial series completion (1 dose).</brief_summary>
	<brief_title>This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama in 2007-2008</brief_title>
	<detailed_description>The study comprises of two independent cross-sectional surveys (Year 8 and Year 10). The first cross-sectional serosurvey will evaluate the long term persistence of immunity approximately 8 years post vaccine administration and the second cross-sectional study will evaluate long term persistence, approximately 10 years post vaccine administration.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Hepatitis A Antibodies</mesh_term>
	<criteria>Subjects whose parent(s)/ LAR(s), in the opinion of the investigator, can and will comply with the requirements of the protocol. Written informed assent/consent obtained from the subject or subject's parent(s)/ LAR(s) of the subject. Children born between 1st January 2005 and 31st December 2007. Available HAV vaccination records. Children who have received either 1 or two doses of Havrix at selected health centres of Panama. Children with ≥ 7 years and &lt; 9 years between last dose and Persistence Visit 1 (Year 8) and children ≥ 9 years and &lt; 11 years between last dose and Persistence Visit 1' (Year 10). Child in care Subjects with history of vaccination with other hepatitis A vaccines other than Havrix. Subjects with known past history of hepatitis A infection, both without vaccination and after they received the last dose of Havrix (1 dose or the complete 2 dose schedule).</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Havrix</keyword>
	<keyword>Cross-sectional seroprevalence survey</keyword>
	<keyword>Panama</keyword>
	<keyword>Long-term persistence</keyword>
	<keyword>Hepatitis</keyword>
</DOC>